Unlike exogenous growth hormone administration, which can lead to constant and potentially excessive levels, Sermorelins stimulation results in a more physiologically relevant episodic release
Instead, a multidistrict litigation (MDL) has been established to manage the numerous personal injury claims related to Ozempic and other GLP-1 medications
Safety, Risks, and Provider Oversight What to know: Lower dose is not lower risk: FDA boxed warnings and contraindications for semaglutide apply at any dose, and adverse events including nausea, gallbladder issues, and rare pancreatitis can still occur, which is why a licensed-provider evaluation and ongoing monitoring are required
How We Ranked the Best Semaglutide Providers When evaluating providers, we considered: Medical screening process Access to licensed healthcare professionals Prescription management Follow-up care Ease of enrollment Overall patient experience Transparency Program flexibility 1
The safety profile of orforglipron has been similar to other incretin-based therapies